...
首页> 外文期刊>Indian journal of pharmacology. >The peak bispectral index time cannot predict early phase propofol pharmacodynamics with effect site-controlled infusion algorithm
【24h】

The peak bispectral index time cannot predict early phase propofol pharmacodynamics with effect site-controlled infusion algorithm

机译:双峰指数峰值时间无法通过有效的位控输注算法预测丙泊酚的早期药效学

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives: The plasma-effect site equilibration rate constant (ke0) of propofol was determined with peak bispectral index (BIS) time (T PEAK) in our previous study. The present study has been conducted to evaluate the ke0's performance with effect site-controlled infusion algorithm. Materials and Methods: Forty unpremedicated patients were randomized to group TE1 (Schnider's pharmacokinetic model with ke0 adapted to T PEAK = 74s) and TE2 (T PEAK = 96s). In stage 1, all patients received propofol with effect-site concentration (Ce) controlled infusion. Once the pump had injected the mass of propofol necessary to achieve pre-set Ce and while the infusion was stopped, target was reset at 0 g/ml. When BIS returned to 80 or above, then, in stage 2, the patients received plasma concentration controlled infusion for 10 min. The time of loss of responsiveness (LOR) and BIS were recorded. The differences of Ce at the time of LOR, lowest BIS between stages 1 and 2, hysteresis loop were used to evaluate the performance of ke0. Results: In both groups, the calculated propofol Ce at the time of LOR in stages 1 and 2 differed significantly (P0.01); the mean lowest BIS in stage 1 were significantly higher than those in stage 2 (P 0.05).The relations of propofol Ce versus BIS revealed the apparent hysteresis loop. Conclusions: The study cannot clinically validate the accuracy of application of ke0 derived from the T PEAK = 74 s of BIS with Schnider propofol pharmacokinetic model.
机译:目的:在我们以前的研究中,用峰双谱指数(BIS)时间(T PEAK)确定丙泊酚的血浆效应位点平衡速率常数(ke0)。进行了本研究以评估效果位控输注算法对ke0的性能。材料和方法:40名未接受药物治疗的患者被随机分为TE1组(施耐德的药物动力学模型,ke0适应T PEAK = 74s)和TE2组(T PEAK = 96s)。在第1阶段,所有患者均接受丙泊酚和效果位点浓度(Ce)控制的输注。一旦泵注入了达到预设Ce所需的丙泊酚质量,并且在停止输注的同时,将目标重置为0 g / ml。当BIS恢复到80或更高时,则在第2阶段,患者接受10分钟的血药浓度控制输注。记录失去反应时间(LOR)和BIS的时间。 LOR时的Ce的差异,第1阶段和第2阶段之间的最低BIS,磁滞回线用于评估ke0的性能。结果:在两组中,LOR时第一阶段和第二阶段的丙泊酚Ce的计算值均存在显着差异(P <0.01);第一阶段的平均最低BIS显着高于第二阶段(P <0.05)。丙泊酚Ce与BIS的关系显示出明显的磁滞回线。结论:该研究无法在临床上验证施耐德丙泊酚药代动力学模型中TPEAK = 74 s的BIS应用ke0的准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号